Yousif Capital Management LLC Buys Shares of 34,497 Indivior PLC $INDV

Yousif Capital Management LLC bought a new stake in shares of Indivior PLC (NASDAQ:INDV) in the fourth quarter, Holdings Channel reports. The fund bought 34,497 shares of the company’s stock, valued at approximately $1,137,000.

A number of other hedge funds have also added to or reduced their stakes in INDV. Goldman Sachs Group Inc. grew its holdings in Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares in the last quarter. Jane Street Group LLC grew its holdings in Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Indivior by 669.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after buying an additional 340,498 shares in the last quarter. Prudential Financial Inc. purchased a new position in Indivior during the 2nd quarter valued at about $207,000. Finally, Walleye Capital LLC purchased a new position in Indivior during the 2nd quarter valued at about $594,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on INDV shares. Northland Securities set a $50.00 target price on Indivior in a report on Tuesday, January 20th. HC Wainwright lifted their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Indivior currently has a consensus rating of “Buy” and a consensus price target of $39.33.

Indivior Trading Down 3.1%

Shares of NASDAQ INDV opened at $31.51 on Friday. Indivior PLC has a 12 month low of $8.69 and a 12 month high of $38.00. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of 19.21 and a beta of 0.88. The business has a 50-day moving average of $31.95 and a 200-day moving average of $31.71.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Friday, February 27th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million. On average, analysts predict that Indivior PLC will post 1.22 earnings per share for the current year.

Insider Transactions at Indivior

In other news, Director Stuart A. Kingsley bought 940 shares of the business’s stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $31.86 per share, with a total value of $29,948.40. Following the completion of the purchase, the director directly owned 5,582 shares in the company, valued at $177,842.52. This represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.74% of the stock is currently owned by corporate insiders.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.